Yahoo · Sep 27, 2026
Could This Cathie Wood Stock Soar in 2027?
This biotech has grabbed plenty of headlines recently.
NT
NASDAQ · NTLA
Intellia Therapeutics, Inc.
Healthcare · Biotechnology
$12.75
Down-$0.38 (-2.98%)
Updated Oct 6, 2026, 8:32 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1B
- P/E ratio
- -2.36
- Dividend yield
- 0.00%
- 52-week range
- $10.15 – $18.48
- Volume
- 4.97M
- Avg. volume
- 8.04M
Price performance · NTLA
NTLA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
NTLA closed at $12.75 after 20 trading sessions, up 0.08% for the selected period.
- Last close
- $12.75
- Period change
- +0.08%
- Period low
- $11.36
- Period high
- $12.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $12.35 | $12.88 | $11.85 | $12.75 | 4.97M |
| Oct 2, 2026 | $12.42 | $12.765 | $12.095 | $12.26 | 4.5M |
| Oct 1, 2026 | $11.98 | $12.655 | $11.82 | $12.12 | 7.45M |
| Sep 30, 2026 | $11.96 | $12.235 | $11.75 | $12.06 | 5.32M |
| Sep 29, 2026 | $11.49 | $12.05 | $11.419 | $12.03 | 5.02M |
| Sep 28, 2026 | $11.72 | $11.8014 | $11.33 | $11.42 | 3.3M |
| Sep 25, 2026 | $12.33 | $12.33 | $11.665 | $11.75 | 2.99M |
| Sep 24, 2026 | $12.13 | $12.21 | $11.62 | $12.16 | 4.81M |
| Sep 23, 2026 | $12.72 | $12.85 | $11.96 | $12.33 | 5.04M |
| Sep 22, 2026 | $12.27 | $12.97 | $12.14 | $12.69 | 3.92M |
| Sep 21, 2026 | $12.50 | $12.65 | $12.14 | $12.22 | 3.74M |
| Sep 18, 2026 | $12.155 | $12.47 | $11.865 | $12.14 | 8.63M |
| Sep 17, 2026 | $11.99 | $12.87 | $11.95 | $12.26 | 5.76M |
| Sep 16, 2026 | $11.46 | $11.75 | $11.37 | $11.49 | 4.59M |
| Sep 15, 2026 | $11.75 | $11.82 | $11.2427 | $11.36 | 3.99M |
| Sep 14, 2026 | $11.645 | $12.11 | $11.645 | $11.87 | 2.6M |
| Sep 11, 2026 | $12.10 | $12.19 | $11.69 | $11.74 | 2.71M |
| Sep 10, 2026 | $11.90 | $11.955 | $11.66 | $11.93 | 3.92M |
| Sep 9, 2026 | $12.50 | $12.82 | $12.19 | $12.21 | 4.93M |
| Sep 8, 2026 | $12.83 | $12.89 | $12.425 | $12.74 | 4.13M |
Latest NTLA news
The latest Smart Investors Daily articles mentioning NTLA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NTLA research
Overview
Company profile and research snapshot.
Company profile
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.69
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Citizens | Market Outperform | — |
| Sep 9, 2026 | Wedbush | Neutral | — |
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 25, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 27, 2026
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn!
Intellia update: Claude AI flags a gene-editing setup but canât replicate it. Lonvo-z targets a 2027 launch; Nex-z enrollment rebounds. Click for more on NTLA stock.
Yahoo · Sep 22, 2026
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy
Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...
Yahoo · Sep 19, 2026
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event. Chief Executive Officer
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
